Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies.

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.

Ruxolitinib for myelofibrosis--an update of its clinical effects.

The new landscape of therapy for myelofibrosis.

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.

Clearing the path for MPN therapy monitoring.

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing.

Emerging drugs for polycythemia vera.

Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial.